Febuxostat in the management of gout: a cost-effectiveness analysis

References

• Kuo C-F, Grainge MJ, Mallen C, et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2014;74:661-7
   PubMed Web of Science ®Google Scholar
• Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009;48(2 Suppl):ii2-8
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011;63:3136-41
   PubMed Web of Science ®Google Scholar
• Wertheimer A, Morlock R, Becker MA. A revised estimate of the burden of illness of gout. Curr Ther Res Clin Exp 2013;75:1-4
   PubMedGoogle Scholar
• Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008;75(5 Suppl):S13-16
   PubMedGoogle Scholar
• Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005;143:499-516
   PubMed Web of Science ®Google Scholar
• Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431-46
   PubMed Web of Science ®Google Scholar
• Feig D. Uric acid: a novel mediator and marker of risk in chronic kidney disease? Curr Opin Nephrol Hypertens 2009;18:526-30
   PubMed Web of Science ®Google Scholar
• Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 2014;15:122
   PubMed Web of Science ®Google Scholar
• Zhang Y, He F, Ding H, et al. Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis. J Huazhong Univ Sci Technol Med Sci 2014;34:476-81
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of ckd and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis 2015;65:543-9
   Google Scholar
• Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol 2008;20:167-72
   PubMed Web of Science ®Google Scholar
• Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966;64:229-58
   PubMed Web of Science ®Google Scholar
• Reach G. Treatment adherence in patients with gout. Joint Bone Spine 2011;78:456-9
   PubMed Web of Science ®Google Scholar
• Joseph-Ridge N. A phase 3, randomized, multicenter, allopurinol and placebo-controlled study assessing the safety and efficacy of oral febuxostat in subjects with gout (APEX) data on file. Deerfield, IL: TAP Pharmaceutical Products Inc/Takeda Pharmaceutical Company Limited, 2004
   Google Scholar
• Joseph-Ridge N. A phase 3, randomized, multicenter study comparing the safety and efficacy of oral febuxostat versus allopurinol in subjects with gout (FACT) data on file. Deerfield, IL: TAP Pharmaceutical Products Inc/Takeda Pharmaceutical Company Limited, 2004
   Google Scholar
• Lademacher C. A Phase 3, randomized, multicenter, double-blind, allopurinol-controlled study assessing the efficacy and safety of oral febuxostat in subjects with gout (CONFIRMS) data on file. Deerfield, IL: TAP Pharmaceutical Products Inc/Takeda Pharmaceutical Company Limited, 2008
   Google Scholar
• Watson Laboratories Inc. Allopurinol [Package Insert] [Internet]. Corona, CA: Watson Laboratories Inc., 2006. http://pi.watson.com/data_stream.asp?product_group=1197&p=pi&language=E. Accessed March 31, 2014
   Google Scholar
• Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61
   PubMed Web of Science ®Google Scholar
• Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010;12:R63
   PubMed Web of Science ®Google Scholar
• Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau. 2010 census data [Internet]. Washington, DC: U.S. Census Bureau, 2011. http://census.gov/2010census/data/. Accessed March 31, 2014
   Google Scholar
• Mikuls TR, Farrar JT, Bilker WB, et al. Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis 2005;64:267-72
   PubMed Web of Science ®Google Scholar
• Xiangyang. The evaluation of clinical outcomes associated with the use of febuxostat and allopurinol in the treatment of gout: reanalysis using the GE EMR database version 2.0 data on file. Deerfield, IL: Takeda Pharmaceutical Company Limited, 2012
   Google Scholar
• Schumacher HR, Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009;48:188-94
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey 20072008 [Internet]. Hyattsville, MD: National Center for Health Statistics, 2009. http://www.cdc.gov/nchs/nhanes/search/nhanes07_08.aspx. Accessed March 31, 2014
   Google Scholar
• Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey 20092010 [Internet]. Hyattsville, MD: National Center for Health Statistics, 2011. http://www.cdc.gov/nchs/nhanes/search/nhanes09_10.aspx. Accessed March 31, 2014
   Google Scholar
• Dalbeth N, Stamp L. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events. Sem Dialysis 2007;20:391-5
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceuticals America, Inc. Uloric (febuxostat) [Package Insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc., 2009
   Google Scholar
• Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56
   PubMed Web of Science ®Google Scholar
• Beard SM, von Scheele BG, Nuki G, et al. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ 2014;15:453-63
   PubMed Web of Science ®Google Scholar
• Halpern MT, Luce BR, Brown RE, et al. Health and economic outcomes modeling practices: a suggested framework. Value Health 1998;1:131-47
   PubMedGoogle Scholar
• Wu EQ, Patel PA, Mody RR, et al. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol 2009;36:1032-40
   PubMed Web of Science ®Google Scholar
• Kuo C-F, Luo S-F, See L-C, et al. Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol 2011;40:116-21
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Incidence of diagnosed diabetes per 1,000 population aged 1879 years, 19802011 [Internet]. Atlanta, GA: Diabetes Public Health Resource, 2012. http://www.cdc.gov/diabetes/statistics/incidence/fig3.htm. Accessed March 31, 2014
   Google Scholar
• Krishnan E, Akhras KS, Sharma H, et al. Serum urate and incidence of kidney disease among veterans with gout. J Rheumatol 2013;40:1166-72
   PubMed Web of Science ®Google Scholar
• Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009;32:1737-42
   PubMed Web of Science ®Google Scholar
• Arias E. United States Life Tables, 2009. National Vital Statistics Report 2014;62:1-63
   PubMedGoogle Scholar
• Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and anti-inflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res 2012;64:1447-61
   PubMed Web of Science ®Google Scholar
• Becker MA, MacDonald PA, Hunt BJ, et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleos Nucleot Nucl 2008;27:585-91
   PubMed Web of Science ®Google Scholar
• Khanna D, Fuldeore M, Meissner B, et al. The incidence of allopurinol hypersensitivity syndrome: a population perspective (abstract 1362). Arthritis Rheum 2008;58:S672-3
   Web of Science ®Google Scholar
• D’Souza A, Fuldeore M, Khanna D, et al. PMS22 Economic impact of allopurinol hypersensitivity syndrome. Value Health 2008;11:A261
   Web of Science ®Google Scholar
• Singh J, Hagerty D, Storgard C, et al. Abstract 143 - Proposed gout treatment guidelines and meeting serum urate and flare goals. Arthritis Rheum 2012;64:S62
   PubMed Web of Science ®Google Scholar
• Hansen LJ, Olivarius N de F, Siersma V. 16-year excess all-cause mortality of newly diagnosed type 2 diabetic patients: a cohort study. BMC Public Health 2009;9:400
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. NEJM 2004;351:1296-305
   PubMed Web of Science ®Google Scholar
• Schulman K. Clinical & economic outcomes in patients with a history of chronic kidney disease & gout initiating therapy with allopurinol or febuxostat. Data on file. Deerfield, IL: TAP Pharmaceutical Products Inc/Takeda Pharmaceutical Company Limited, 2014
   Google Scholar
• Wertheimer AI, Davis MW, Lauterio TJ. A new perspective on the pharmacoeconomics of colchicine. Curr Med Res Opin 2011;27:931-7
   PubMed Web of Science ®Google Scholar
• American Medical Association. AMA CodeManager: CPT Code/Relative Value Search [Internet].Chicago, IL: American Medical Association, 2013. https://ocm.ama-assn.org/OCM/CPTRelativeValue Search.do. Accessed March 31, 2014
   Google Scholar
• Avalere Health LLC. Trendwatch 2013 chartbook: trends affecting hospitals and health systems [Internet]. Chicago, IL: American Hospital Association, 2013. http://www.aha.org/research/reports/index.shtml. Accessed March 31, 2014
   Google Scholar
• Walk-In Lab. Uric acid serum test [Internet]. Kidney Tests. Mandeville, LA: Walk In Lab, LLC, 2014. http://www.walkinlab.com/kidney-tests/uricacidserumtest.html. Accessed March 31, 2014
   Google Scholar
• Halpern R, Fuldeore MJ, Mody RR, et al. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 2009;15:3-7
   PubMed Web of Science ®Google Scholar
• Hoerger T, Witterborn JS, Segal JE, et al. A health policy model of CKD 2: The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis 2010;55:463-73
   PubMed Web of Science ®Google Scholar
• U.S. Renal Data System. USRDS 2011 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Chapter 11 [Internet]. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011. http://www.usrds.org/atlas11.aspx. Accessed March 31, 2014
   Google Scholar
• Neogi T, Chen C, Chaisson C, et al. Abstract 151- Management of Gout Attacks in the Community. Arthritis Rheum 2012;64:S66
   Web of Science ®Google Scholar
• Gandhi PK, Gentry WM, Ma Q, et al. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. J Manag Care Spec Pharm 2015;21:165-75
   PubMed Web of Science ®Google Scholar
• Meltzer M, Pizzi LT, Jutkowitz E. Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout. Evid Based Med 2012;17:105-8
   PubMedGoogle Scholar
• Bureau of Labor Statistics. Consumer price index - all urban consumers. Medical Care [Internet]. Washington, DC: Bureau of Labor Statistics, 2014. http://data.bls.gov/cgi-bin/surveymost?cu. Accessed March 31, 2014
   Google Scholar
• Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. PharmacoEconomics 2011;29:133-40
   PubMed Web of Science ®Google Scholar
• Jutkowitz E, Choi HK, Pizzi LT, et al. Cost-effectiveness of allopurinol and febuxostat for the management of gout. Ann Intern Med 2014;161:617-26
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 2012;125:679-87.e1
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-93
   PubMed Web of Science ®Google Scholar
• Whelton A, MacDonald PA, Chefo S, et al. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgrad Med 2013;125:106-14
   PubMed Web of Science ®Google Scholar
• Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013;72:826-30
   PubMed Web of Science ®Google Scholar
• Stamp LK, O'Donnell JL, Zhang M, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011;63:412-21
   PubMed Web of Science ®Google Scholar
• Reinders MK, Haagsma C, Jansen TLTA, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis 2009;68:892-7
   PubMed Web of Science ®Google Scholar
• Truven Health Analytics. RED BOOK Online [Internet]. Ann Arbor, MI: Truven Health Analytics, 2014. http://www.micromedexsolutions.com. Accessed March 31, 2014
   Google Scholar